(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

Tuesday, October 28, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

Achievement of Treat to Target Measures with Upadacitinib in Patients with Systemic Lupus Erythematosus: Phase 2 Randomized Sleek Clinical Trial Results
Abstract Poster Presenter: Eric Morand, MD, PhD – Monash University
10:30 AM - 12:30 PM Central Time

Allogenic Anti- CD19 CAR-T Cells Induce Remission in Refractory Systemic Lupus Erythematosus
Abstract Poster Presenter: Qian Tan, MD, PhD – BRL Medicine Inc.
10:30 AM - 12:30 PM Central Time

Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Abstract Poster Presenter: Jeff Ellis, PharmD, MS – GSK
10:30 AM - 12:30 PM Central Time

Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Abstract Poster Presenter: Ahmad Alomari, MD – UCF / North Florida Hospital
10:30 AM - 12:30 PM Central Time

Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Abstract Poster Presenter: Aaron Smith, MD, MS – University of North Carolina
10:30 AM - 12:30 PM Central Time

CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
Abstract Poster Presenter: Qiong Fu, MD (she/her/hers) – Renji Hospital
10:30 AM - 12:30 PM Central Time

Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Abstract Poster Presenter: Pablo Martinez Calabuig, Sr, MD – HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN/ Escuela de doctoradoUniversidad Católica de Valencia San Vicente Mártir, Valencia, Spain
10:30 AM - 12:30 PM Central Time

Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
Abstract Poster Presenter: Richard A. Furie, MD – Northwell
10:30 AM - 12:30 PM Central Time

Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Abstract Poster Presenter: Cynthia Aranow, MD – Feinstein Institutes for Medical Research
10:30 AM - 12:30 PM Central Time

Development of Consensus Statements on Glucocorticoid Use in Systemic Lupus Erythematosus
Abstract Poster Presenter: Wen-Nan Huang, MD, PhD. (he/him/his) – Taichung Veterans General Hospital
10:30 AM - 12:30 PM Central Time

Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Abstract Poster Presenter: Bruno Flamion, MD, PhD (he/him/his) – Viatris Innovation GmbH
10:30 AM - 12:30 PM Central Time

Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Abstract Poster Presenter: Richard Furie, MD – Northwell
10:30 AM - 12:30 PM Central Time

Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Abstract Poster Presenter: Milena Delai, MD – Beth Israel Deaconess Medical Center
10:30 AM - 12:30 PM Central Time

Hydroxychloroquine-Induced Retinopathy in Systemic Lupus Erythematosus: Predictors of Progression Following Drug Discontinuation
Abstract Poster Presenter: Emily Gutowski, MD – NYU
10:30 AM - 12:30 PM Central Time

IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
Abstract Poster Presenter: Qian Zheng, PhD – ImmuneCare Biopharmaceuticals(Shanghai) Co., LTD
10:30 AM - 12:30 PM Central Time

Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Abstract Poster Presenter: Trever Greene, PhD – Fate Therapeutics
10:30 AM - 12:30 PM Central Time

Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab
Abstract Poster Presenter: Fumin Qi, n/a – Tianjin Medical University General Hospital
10:30 AM - 12:30 PM Central Time

Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
Abstract Poster Presenter: Justin Arnold, BA (he/him/his) – Northwestern Feinberg School of Medicine
10:30 AM - 12:30 PM Central Time

Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Abstract Poster Presenter: Kenza EL OUAZZANI ECH CHAHDI, BS – Bordeaux University
10:30 AM - 12:30 PM Central Time

Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Abstract Poster Presenter: Maria Leandro, MD,PhD,FRCP – UCL/UCLH
10:30 AM - 12:30 PM Central Time

Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren's Syndrome: An Analysis Using Japanese Inpatient Database
Abstract Poster Presenter: Hiroshi Shiba, MD – Suwa central hospital
10:30 AM - 12:30 PM Central Time

Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Abstract Poster Presenter: Pooja Patel, DO – Ann and Robert H. Lurie Children's Hospital of Chicago
10:30 AM - 12:30 PM Central Time

Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Abstract Poster Presenter: Karen Worley, PhD, MS – GSK, Global Real-World Evidence & Health Outcomes Research
10:30 AM - 12:30 PM Central Time

Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases
Abstract Poster Presenter: Jan Davidson-Moncada, PhD, MBBS – Bioheng
10:30 AM - 12:30 PM Central Time

Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Abstract Poster Presenter: Danae-Mona Nöthling, MD – University Clinic Erlangen, Germany
10:30 AM - 12:30 PM Central Time

RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Abstract Poster Presenter: Saira Sheikh, MD – University of North Carolina at Chapel Hill
10:30 AM - 12:30 PM Central Time

Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Abstract Poster Presenter: Haiting Wang, MD, PhD (she/her/hers) – Renji Hospital
10:30 AM - 12:30 PM Central Time

SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Abstract Poster Presenter: Ahmad Alomari, MD – UCF / North Florida Hospital
10:30 AM - 12:30 PM Central Time

Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
Abstract Poster Presenter: Irene Carrión-Barberà, MD, PhD – University of Washington
10:30 AM - 12:30 PM Central Time

Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
10:30 AM - 12:30 PM Central Time

Tofacitinib Lowers Markers of Photosensitivity in Patients with Cutaneous Lupus Erythematosus
Abstract Poster Presenter: J. Michelle Kahlenberg, MD, PhD – University of Michigan
10:30 AM - 12:30 PM Central Time

Use of Voclosporin in Pediatric Patients: A Summary of Available Data from Post-marketing Reports
Abstract Poster Presenter: Eugenia Chock, MD – Yale School of Medicine
10:30 AM - 12:30 PM Central Time

WITHDRAWN